Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
73 hedge funds and large institutions have $142M invested in Anthera Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 8 closing their positions.
375% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 8
115% more capital invested
Capital invested by funds: $65.9M → $142M (+$75.7M)
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
70% more funds holding
Funds holding: 43 → 73 (+30)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less call options, than puts
Call options by funds: $1.2M | Put options by funds: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.08M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.95M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.82M |
| 4 |
SCM
Sio Capital Management
New York
|
+$1.38M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$6.08M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.32M |
| 3 |
GCM
Gruss Capital Management
New York
|
-$2.03M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$674K |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$473K |
ANTH Hedge Fund Activity: Q2 2015 in Review
73 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q2 2015, worth a combined $142M — up 115% from $65.9M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ANTH positions and 8 closed out — a net gain of 30 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $5.08M. The largest seller was Broadfin Capital, cutting an estimated $6.08M.
- 73 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q2 2015, up from 43 in Q1 2015.
- Funds reported $142M of Anthera Pharmaceuticals, Inc. stock for Q2 2015, up 115% quarter-over-quarter.
- 38 funds opened new Anthera Pharmaceuticals, Inc. positions in Q2 2015 and 8 closed out, a net change of +30 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $5.08M added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q2 2015 was Broadfin Capital, an estimated $6.08M sold.
Based on aggregated 13F filings for Q2 2015.